Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.~Key Inclusion Criteria:~* Histologic diagnosis of unresectable stage III or IV metastatic melanoma~* Prior ipilimumab induction treatment (3 mg/kg)~* Documented disease control \[Stable Disease ≥3 months or Partial Response/Complete Response\] after ipilimumab induction~* Documented progressive disease following disease control~Key Exclusion Criteria:~* Patients with brain metastasis are excluded, unless they are free of neurologic symptoms related to metastatic brain lesions and do not receive systemic corticosteroid therapy for the purpose of reducing intracranial inflammation in the 10 days prior to beginning retreatment with ipilimumab~* Any intervening anticancer therapy between last dose of ipilimumab induction and ipilimumab retreatment on study~* Patients who experienced any grade 3 immune-related adverse event (irAE) (except for endocrinopathies where clinical symptoms were controlled with appropriate hormone replacement therapy) or any grade 4 toxicity during prior treatment with ipilimumab~* Patients with a prior irAE that has not improved to grade 1 or better at randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ipilimumab, 3 mg/kg (Type: EXPERIMENTAL): Participants received ipilimumab, 3 mg/kg, by intravenous infusion, every 3 weeks for a total of 4 doses or until disease progression, unacceptable toxicity, or withdrawal of consent
- Chemotherapy (Type: ACTIVE_COMPARATOR): Participants received the investigator's choice of chemotherapy, administered per package instructions.

Based on this trial design, predict the completion outcome and termination type (if applicable).